Type and hit ENTER

ProAxsis Limited is a commercial-stage diagnostics company, based in Northern Ireland, and with a rapidly growing client list of pharmaceutical companies and academic laboratories.

ProAxsis specialises in four key areas of business:

ProteaseTag®
Active Neutrophil Elastase Immunoassay
  • Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.
NEATstik®
Neutrophil Elastase Airways Test
  • Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.
Clinical research services
services for both academic and pharmaceutical company researchers
  • Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.
R&D Projects
are supported by a variety of external partners
  • ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners. We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.

ProteaseTag® immunoassay - Activity-based immunoassay kits

Activity-based immunoassay kits – Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.

Rapid point-of-care tests – NEATstik®

Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.

Activity-based immunoassay kits

Activity-based immunoassay kits – Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.

Rapid point-of-care tests – NEATstik®

Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.

Clinical research services

Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.

R&D Projects

ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners. We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.

Welcome to ProAxsis

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease, using its patented ProteaseTag® technology.

ProAxsis specialises in four key areas of business:-

  • Activity-based immunoassay kits – Our ProteaseTag® immunoassay for measuring active neutrophil elastase was registered with a CE Mark in 2016, and immunoassays for other protease targets are in development.

 

  • Rapid point-of-care tests – NEATstik®, a lateral flow test for measuring active neutrophil elastase at point-of-care, was registered with a CE Mark in September 2017.

 

  • Clinical research services – Our experienced team can provide a number of services for both academic and pharmaceutical company researchers, and are able to offer sample analysis at our purpose-built laboratory for a range of proteases and other inflammatory biomarkers.

 

  • R&D Projects – ProAxsis has a number of R&D projects ongoing, whch are supported by a variety of external partners.  We are also able to conduct bespoke R&D projects at the request of academic groups or pharmaceutical companies.

Introduction As 2022 commences, I am pleased to provide an update on the progress made with regard to a number of the company’s key objectives announced during 2021.  The global coronavirus pandemic continues to create uncertainty in many markets, including in Respiratory Medicine research, but based on …

January 7, 2022

As part of its ongoing expansion plans, ProAxsis Limited, the Belfast-based diagnostics company, is pleased to announce the appointment of Alison Gillan as its new Management Accountant.  Alison Gillan joins the company as Management Accountant.  Alison comes from private practice and has broad experience of in-house accounting …

January 6, 2022

Dr Darragh McCafferty, ProAxsis’ Head of Assay Development, will be presenting new data on the company’s ongoing project to develop a quantitative version of its neutrophil elastase point-of-care test (NEATstik®) at the Irish Thoracic Society (ITS) annual conference, taking place in virtual format between the 19th-20th November.  …

November 15, 2021
GET CONNECTED
RECENT POSTS
ABOUT ME
LIFESTYLE
SHOP ONLINE
old Home - ProAxsis